Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Role of a novel immune modulating DDR2-expressing population in silica-induced pulmonary fibrosis.

McDonald LT, Johnson SD, Russell DL, Young MRI, LaRue AC.

PLoS One. 2017 Jul 10;12(7):e0180724. doi: 10.1371/journal.pone.0180724. eCollection 2017.

2.

Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.

Levingston CA, Young MRI.

Cancers (Basel). 2017 Jun 2;9(6). pii: E62. doi: 10.3390/cancers9060062.

3.

Redirecting the focus of cancer immunotherapy to premalignant conditions.

Young MR.

Cancer Lett. 2017 Apr 10;391:83-88. doi: 10.1016/j.canlet.2017.01.022. Epub 2017 Jan 24. Review.

4.

Cancer Immunology with a Focus on Understudied Cancers as Targets for Immunotherapy.

Young MR.

Int J Mol Sci. 2017 Jan 11;18(1). pii: E127. doi: 10.3390/ijms18010127.

5.

Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.

Levingston CA, Young MR.

Int J Cancer. 2017 Apr 1;140(7):1609-1619. doi: 10.1002/ijc.30543. Epub 2017 Jan 24.

6.
7.

Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine.

Gattoni-Celli S, Young MR.

Int J Mol Sci. 2016 Sep 2;17(9). pii: E1465. doi: 10.3390/ijms17091465.

8.

Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.

Young MR.

J Clin Cell Immunol. 2016 Jun;7(3):431. Epub 2016 Jun 20.

9.

PTSD, a Disorder with an Immunological Component.

Wang Z, Young MR.

Front Immunol. 2016 Jun 6;7:219. doi: 10.3389/fimmu.2016.00219. eCollection 2016. Review.

10.

Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Johnson SD, Levingston C, Young MR.

Anticancer Res. 2016 Jul;36(7):3261-70.

11.

An exploratory approach demonstrating immune skewing and a loss of coordination among cytokines in plasma and saliva of Veterans with combat-related PTSD.

Wang Z, Mandel H, Levingston CA, Young MRI.

Hum Immunol. 2016 Aug;77(8):652-657. doi: 10.1016/j.humimm.2016.05.018. Epub 2016 May 20.

12.

Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.

Young MR, Levingston CA, Johnson SD.

Int J Cancer. 2016 May 15;138(10):2487-98. doi: 10.1002/ijc.29989. Epub 2016 Jan 28.

14.
15.

Skewing of immune cell cytokine production by mediators from adipocytes and endothelial cells.

Vielma SA, Klein RL, Levingston CA, Young MR.

Adipocyte. 2014 Apr 1;3(2):126-31. doi: 10.4161/adip.28287. Epub 2014 Feb 25.

16.

Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer.

Johnson SD, De Costa AM, Young MR.

Cancers (Basel). 2014 Apr 2;6(2):756-70. doi: 10.3390/cancers6020756.

17.

Premalignant lesions skew spleen cell responses to immune modulation by adipocytes.

Vielma SA, Klein RL, Levingston CA, Young MR.

Anticancer Res. 2013 May;33(5):1809-18.

PMID:
23645725
18.

Adipocytes as immune regulatory cells.

Vielma SA, Klein RL, Levingston CA, Young MR.

Int Immunopharmacol. 2013 Jun;16(2):224-31. doi: 10.1016/j.intimp.2013.04.002. Epub 2013 Apr 13.

19.

Immunological modulation by 1α,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck.

Walker DD, Reeves TD, de Costa AM, Schuyler C, Young MR.

Cytokine. 2012 Jun;58(3):448-54. doi: 10.1016/j.cyto.2012.03.002. Epub 2012 Mar 24.

Supplemental Content

Loading ...
Support Center